Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/2010
08/26/2010WO2010095463A1 Immunopotentiating composition and process for producing same
08/26/2010WO2010095461A1 Novel monoclonal antibody, and use thereof
08/26/2010WO2010095428A1 Foxm1 peptides and vaccines containing the same
08/26/2010WO2010095422A1 Therapeutic agent for malignant tumor
08/26/2010WO2010095364A1 Jarid1b for target gene of cancer therapy and diagnosis
08/26/2010WO2010095270A1 Anti-human α9 integrin antibody and use thereof
08/26/2010WO2010095042A2 Pyridocarbazole type compounds and applications thereof
08/26/2010WO2010094981A2 Antibody therapy
08/26/2010WO2010094755A1 Carboxamide compounds and their use as calpain inhibitors
08/26/2010WO2010094695A1 Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases
08/26/2010WO2010094622A1 3, 3' -spiroindolinone derivatives as anticancer agents
08/26/2010WO2010094609A1 Pharmaceutical composition containing inhibiting agents of protein methyltransferase i and use thereof to treat tumor diseases
08/26/2010WO2010094405A1 Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof
08/26/2010WO2010076033A9 Toluidine sulfonamides and their use
08/26/2010WO2010065825A3 Thieno [3, 2-c] pyridine derivatives as kinase inhibitors for use in the treatment of cancer
08/26/2010WO2010060940A3 Hsp90 inhibitors for therapeutic treatment
08/26/2010WO2010045377A3 Pyrimidine non-classical cannabinoid compounds and related methods of use
08/26/2010WO2010032880A3 Kinase inhibitory substances for cancer
08/26/2010WO2010019701A3 Diaryl urea derivatives
08/26/2010WO2010005704A3 Novel helper plasmid, defective sindbis viral vectors and methods of use thereof
08/26/2010WO2009140469A3 Dosage regimen comprising ap02l/trail, anti-vegf / anti-cd20 and chemotherapy to treat nsclc or non-hodgkin's lymphoma, respectively
08/26/2010WO2009140177A3 Anti-fn14 antibodies and uses thereof
08/26/2010WO2009135614A3 Use of a virus regimen for the treatment of diseases
08/26/2010US20100217045 Composition to enhance the bioavailability of curcumin
08/26/2010US20100216987 Synthesis of naturally occuring ecteinascidins and related compounds
08/26/2010US20100216976 Sodium-independent transporter carrying acidic amino acid and its gene
08/26/2010US20100216886 Polymorphs of n2-(1,1'-biphenyl-4-ylcarbonyl)-n1-[2-(4-fluorophenyl)-1,1-dimethylethyl]-l-alpha-glutamine
08/26/2010US20100216871 Use of compounds having ccr antagonism
08/26/2010US20100216869 Artemisinin derivatives for the treatment of melanoma
08/26/2010US20100216868 Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
08/26/2010US20100216867 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
08/26/2010US20100216865 MicroRNA COMPOSITIONS IN THE TREATMENT OF VEGF-MEDIATED DISORDERS
08/26/2010US20100216859 Curcumin analog compositions and related methods
08/26/2010US20100216858 Bendamustine cyclopolysaccharide compositions
08/26/2010US20100216853 Methods and Compositions for Modulating P300/CBP Activity
08/26/2010US20100216839 Pim kinase inhibitors and methods of their use
08/26/2010US20100216832 Method for Assaying FTO (2-Oxoglutarate Dependent Oxygenase) Activity
08/26/2010US20100216828 Methods and compositions for treating cancers
08/26/2010US20100216826 Polymorphisms in Voltage-Gated Sodium Channel Alpha 1-Subunit as Markers for Therapy Selection
08/26/2010US20100216824 Anti-cancer cyclopenta [G]quinazonline compounds
08/26/2010US20100216823 Spirocyclic Derivatives
08/26/2010US20100216820 Thienopyrimidiones for treatment of inflammatory disorders and cancers
08/26/2010US20100216817 Antitumoral Tetrahydro-Pyrimidines
08/26/2010US20100216811 Furo[3. 2-b] pyrrol derivatives
08/26/2010US20100216810 Heterocyclic compound and use thereof
08/26/2010US20100216808 Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
08/26/2010US20100216806 Ortho aminoamides for the treatment of cancer
08/26/2010US20100216804 Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
08/26/2010US20100216802 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
08/26/2010US20100216801 Thiazolones for use as pi3 kinase inhibitors
08/26/2010US20100216797 Preparation of thioarabinofuranosyl compounds and use thereof
08/26/2010US20100216796 N-hydroxy-naphthalene dicarboxamide and n-hydroxy-biphenyl-dicarboxamide compounds as histone deacetylase inhibitors
08/26/2010US20100216795 Tnik inhibitor and the use
08/26/2010US20100216791 Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors
08/26/2010US20100216789 Rho-kinase inhibitors
08/26/2010US20100216788 Fused heterocyclic compound
08/26/2010US20100216786 New compounds
08/26/2010US20100216782 Hydroxybenzamide derivatives and their use as inhibitors of hsp90
08/26/2010US20100216781 mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY
08/26/2010US20100216779 Imidazopyridine Kinase Inhibitors
08/26/2010US20100216776 Assays for S100 inhibitors
08/26/2010US20100216770 Inhibitors of the Interaction Between MDM2 and P53
08/26/2010US20100216767 Quinazolines for pdk1 inhibition
08/26/2010US20100216766 Inhibitors of VEGF Receptor and HGF Receptor Signalling
08/26/2010US20100216765 Kinase inhibitors
08/26/2010US20100216758 Pyridone Compounds
08/26/2010US20100216756 Compositions and methods for suppressing endometrial proliferation
08/26/2010US20100216755 Anti-tumor agent
08/26/2010US20100216743 Therapy-enhancing glucan
08/26/2010US20100216737 Inactivation of miR-34a by abberant CpG methylation in cancer
08/26/2010US20100216736 2'-cyanopyrimidine nucleoside compound
08/26/2010US20100216729 Cancer cell growth inhibition by black bean (Phaseolus vulgaris L) extracts
08/26/2010US20100216728 New use of specific cyklolignans
08/26/2010US20100216724 Use of fibronectin fragment (196-203 ) as a therapeutic agent
08/26/2010US20100216722 Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent
08/26/2010US20100216718 Cancer Classification and Methods of Use
08/26/2010US20100216716 Cell-Permeable Peptide Inhibitors Of The JNK Signal Transduction Pathway
08/26/2010US20100216713 Novel compositions and methods in cancer associated with altered expression of prlr
08/26/2010US20100216702 Vegf analogs and methods of use
08/26/2010US20100216698 Liquid formulations of g-csf
08/26/2010US20100216696 Compounds and methods for treating cancer
08/26/2010US20100216689 Cytotoxic t cell activator comprising ep4 agonist
08/26/2010US20100216688 Peptidomimetic macrocycles
08/26/2010US20100215773 Use of Quinazoline Derivative ZD6474 Combined With Platinum Compounds and Optionally Ionising Radiation in the Treatment of Diseases Associated With Angiogenesis and/or Increased Vascular Permeability
08/26/2010US20100215772 Aminopyrimidines useful as kinase inhibitors
08/26/2010US20100215760 Intrinscially fluorescent carbon nanospheres and a process thereof
08/26/2010US20100215751 Methods and compositions for treating recurrent cancer
08/26/2010US20100215743 Composition and drug delivery of bisphosphonates
08/26/2010US20100215730 Compositions for Nasal Administration of Phenothiazines
08/26/2010US20100215729 Oligonucleotide analogues incorporating 5-aza-cytosine therein
08/26/2010US20100215727 Stabilized picoplatin dosage form
08/26/2010US20100215724 Microcapsule Nanotube Devices for Targeted Delivery of Therapeutic Molecules
08/26/2010US20100215698 Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response
08/26/2010US20100215697 Methods and materials for making and using vaccines
08/26/2010US20100215678 Ras Mutation and Compositions and Methods Related Thereto
08/26/2010US20100215677 Pdz domain interactions and lipid rafts
08/26/2010US20100215676 Kdr peptides and vaccines comprising the same
08/26/2010US20100215674 Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
08/26/2010US20100215671 Combination Therapy With Antibody-Drug Conjugates
08/26/2010US20100215670 Immunotoxin Fusions Comprising An Antibody Fragment and a Plant Toxin Linked by Protease Cleavable Linkers
1 ... 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 ... 2211